軽度の認知障害における多層白質変性に関連した認知機能障害
Yu Chen1, Tiantian Liu2, Li-Zhi Cao1
1School of Medical Technology, Beijing Institute of Technology, Haidian District, Beijing, China.
Molecular psychiatry
|August 27, 2025
まとめ
軽度の認知障害 (MCI) は,認知機能に影響する白質 (WM) の損傷を含む. この研究は,WMの微細構造の変化が プロドロマ性認知症の認知低下を媒介することを明らかにしています.
科学分野:
- 神経イメージング
- 神経科学
- 神経学
背景:
- 軽度の認知障害 (MCI) は認知障害と白質 (WM) の変化によって特徴づけられる認知症の前臨床段階である.
- WMの微細構造の変化とその認知への影響を理解することは,前兆性認知症の早期診断と介入に不可欠です.
研究 の 目的:
- MCIの患者に複数のスケールでWMの微細構造の退化を調査する.
- WMの変異と認知機能障害の関係における構造コネクトームの媒介的な役割を分析する.
主な方法:
- 50人のMCI患者と75人の健康な対照群でFixelベースの分析 (FBA) を用いた.
- 構造的コネクトーム分析は,WM認知関連に対するネットワークレベルの影響を調査する.
主要な成果:
- MCIの患者は,繊維の密度とコンシューラとアソシエーションの繊維の横断の減少を含む,繊維特有のWM障害を広く示した.
- WMの微小構造的変異は多領域認知障害と関連していました.
- 視覚ネットワークと突起ネットワークの構造的なコネクトームは,WMの損傷と言語と記憶機能の障害の間のリンクを媒介しました.
結論:
- 異なるスケールでのWMの微細構造の損傷は,MCIの認知低下に寄与します.
- ネットワークレベルの相互作用は,特に視覚的および突起のネットワークは,特定の認知領域に対するWMの変化の影響を媒介する上で重要です.
さらに関連する動画
12:18A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
7.6K
06:23The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
32.7K
関連する概念動画
01:26Alzheimer's Disease: Overview
666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666
01:30Dementia
165
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
165
01:30Cognitive Development During Adulthood
255
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
255
01:23Role of Neurotransmitters in Memory
964
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
964
01:22Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
206
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
206